Simultaneous Estimation of Ivabradine Hydrochloride and Trimetazidine Dihydrochloride in Bulk and Tablet Formulation

Download PDF

Beta-blockers are the most commonly used in the treatment of ischemic heart disorder. However, when beta-blockers develop intolerance, newer drug therapy is the best alternative treatment. Ivabradine hydrochloride and Trimetazidine dihydrochloride are both antianginal drugs. However, there is no method for determining the combination of both of these drugs. Hence, this work provides a new and simple UV (Ultraviolet) spectrophotometric-based simultaneous estimation of Ivabradine hydrochloride (IBH) in the presence of Trimetazidine dihydrochloride (TMZ) in bulk as well as tablet form.

Firstly, the lambda max of both drugs was determined for Ivabradine hydrochloride (286 nm) and Trimetazidine dihydrochloride (231 nm). Calibration curves for Ivabradine hydrochloride and Trimetazidine dihydrochloride were plotted by measuring the absorbance at a specific concentration, and it was found that both drugs obeyed linearity with regression values (R²) of 0.999. The minimum concentration required (limit of detection) for UV spectrophotometric detection of Ivabradine hydrochloride was determined to be 2.350 μg/mL with a limit of quantification (LOQ) of 7.122 μg/mL, similarly the limit of detection (LOD) for Trimetazidine dihydrochloride observed to be 3.790 μg/mL with limit of detection of 11.485 μg/mL. The precision study showed a percentage deviation (relative standard deviation (RSD)) within acceptable values (RSD < 2.0%). The recovery value of both drugs was in the range of 98% to 102%, demonstrating accuracy. Based on the results, it is concluded that the proposed UV spectroscopic technique is new but simple, precise, reliable, and affordable for the simultaneous determination of Ivabradine hydrochloride and Trimetazidine dihydrochloride.